Mirtazapine treatment of obsessive-compulsive disorder [6]

Journal of Clinical Psychopharmacology

Volumn 21, Issue 5, 2001, Pages 537-539

  Koran, L M ^a   Quirk, T ^a   Lorberbaum, J P ^a   Elliot, M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; SEROTONIN 2 RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DYSTHYMIA; FEMALE; HUMAN; LETTER; MALE; OBSESSION; PRIORITY JOURNAL; SEROTONINERGIC TRANSMISSION;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIANSERIN; OBSESSIVE-COMPULSIVE DISORDER; SEVERITY OF ILLNESS INDEX;

EID: 0034796603     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200110000-00016     Document Type: Letter

References (16)

1. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis
2. The serotonin hypothesis of obsessive-compulsive disorder: Implications of pharmacologic challenge studies
3. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
4. The pharmacological profile of mirtazapine
5. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability
6. A rating scale for depression
7. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder
8. Previous SRI treatment and efficacy of sertraline for OCD: Combined analysis of 4 multicenter trials
9. The potential role of 5-HT1D receptors in the pathophysiology and treatment of obsessive-compulsive disorder
10. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses
11. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
12. Update in the pharmacotherapy of depression
13. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety